Rotz, Seth J. http://orcid.org/0000-0003-2896-1113
Bhatt, Neel S. http://orcid.org/0000-0003-2033-1125
Hamilton, Betty K. http://orcid.org/0000-0003-1252-6539
Duncan, Christine
Aljurf, Mahmoud http://orcid.org/0000-0003-3942-7370
Atsuta, Yoshiko http://orcid.org/0000-0003-4404-2870
Beebe, Kristen
Buchbinder, David
Burkhard, Peggy
Carpenter, Paul A.
Chaudhri, Naeem
Elemary, Mohamed
Elsawy, Mahmoud http://orcid.org/0000-0001-9872-2471
Guilcher, Gregory M. T.
Hamad, Nada http://orcid.org/0000-0001-7929-1450
Karduss, Amado http://orcid.org/0000-0001-8372-102X
Peric, Zinaida http://orcid.org/0000-0001-9458-8025
Purtill, Duncan http://orcid.org/0000-0002-0408-8455
Rizzo, Douglas http://orcid.org/0000-0003-1474-1152
Rodrigues, Morgani
Ostriz, Maria Belén Rosales
Salooja, Nina http://orcid.org/0000-0001-5668-9001
Schoemans, Helene http://orcid.org/0000-0002-7568-8239
Seber, Adriana
Sharma, Akshay http://orcid.org/0000-0003-3281-2081
Srivastava, Alok
Stewart, Susan K.
Baker, K. Scott http://orcid.org/0000-0003-3377-1648
Majhail, Navneet S.
Phelan, Rachel http://orcid.org/0000-0001-5252-9991
Article History
Received: 5 December 2023
Revised: 8 December 2023
Accepted: 19 December 2023
First Online: 27 February 2024
Competing interests
: The authors report no conflicts of interest relevant to this work. The authors report the following financial relationships. YA: Lecture fee: Otsuka Pharmaceutical Co., Ltd; CHUGAI PHARMACEUTICAL CO., LTD.; Novartis Pharma KK; AbbVie GK; Honorarium: Meiji Seika Pharma Co, Ltd.; Consultant fee: JCR Pharmaceuticals Co., Ltd.; Kyowa Kirin Co., Ltd. GG: Principal Investigator of Project Sickle Cure, a Sickle Cell Transplant Advocacy and Research Alliance Study partially funded by bluebirdbio. I serve on the steering committee of a STAR clinical trial for which Bristol Myers Squibb has provided funding. NM: Consultant for Anthem, Inc; Stock in HCA Healthcare. Rachel Phelan: Bluebirdbio: advisory board. Amgen: research funding. SR: Medical Monitor for Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT). HS: personal fees: Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS); research grants from Novartis and the BHS. non-financial support from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research). AS: consultant fee from Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, Sangamo Therapeutics and Editas Medicine. Medical Monitor for Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT). Research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. AS is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907) and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Dr Sharma’s institution.